Table 1.

Demographic data of 219 patients who underwent transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Variable
Age (years)	61.4 ± 7.6 [27–86]
Sex
Male	165 (165/219; 75.3%)
Female	54 (54/219; 24.7%)
HCC size (cm)	3.8 ± 3.6 [1–33]
AST (U/L)	102 ± 60 [26–198]
ALT (U/L	92 ± 64 [25–201]
CR (mg/dL)	1.0 ± 0.9 [0.4–10.7]
INR	1.2 ± 0.2 [0.9–1.8]
Albumin (g/dL)	3.2 ± 0.6 [1.1–5.2]
Total bilirubin (mg/dL)	1.3 ± 0.7 [0.2–4.2]
Direct bilirubin (mg/dL)	0.4 ± 0.3 [< 0.1–2]
MELD score	10.3 ± 3.1 [1–22]
Number of TACE treatments	1.4 ± 0.7 [1–6]
Selectivity of treatment
Hemiliver	29 (29/353; 8.1%)
> Sectional but < Hemiliver	50 (50/353; 14.2%)
Sectional	140 (140/353; 39.7%)
Segmental	134 (134/353; 38%)

HCC: hepatocellular carcinoma; TACE: Transarterial chemoembolization; Na: Sodium; INR: International normalization ratio; MELD: Model for end-stage liver disease. Quantitative variables are expressed as mean ± standard deviations, followed by ranges in brackets. Qualitative variables are expressed as raw numbers. Numbers in parentheses are proportions followed by percentages